Gastrointestinal Therapeutics Market Report 2025

The gastrointestinal therapeutics market size has grown strongly in recent years. It will grow from $39.99 billion in 2024 to $42.3 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. Growth during the historic period was driven by increased government healthcare spending, higher rates of early diagnosis, expanded awareness campaigns about gut health, a rise in lifestyle-related digestive disorders, and the adoption of multidisciplinary treatment methods.

The gastrointestinal therapeutics market size is expected to see strong growth in the next few years. It will grow to $52.41 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. Growth in the forecast period is expected to result from increasing demand for biologics and targeted treatments, greater adoption of personalized medicine, a growing patient preference for combination therapies, increased focus on microbiome-targeted treatments, and a rise in antibiotic-related gastrointestinal complications. Key trends during this period include advancements in technology integration for endoscopic devices, development of microbiome-based therapies, the use of digital health and remote monitoring, incorporation of multi-omics data in therapy development, and innovations in acid suppression treatments.

The increasing prevalence of inflammatory bowel diseases is expected to drive the growth of the gastrointestinal therapeutics market in the future. Inflammatory bowel disease (IBD) is a chronic illness characterized by inflammation of the digestive tract, mainly including Crohn's disease and ulcerative colitis. The rise in IBD cases is linked to genetic susceptibility, which leads to an abnormal immune response to gut microbes. Gastrointestinal therapeutics work by targeting the underlying inflammation, regulating digestive functions, and easing symptoms to improve patient outcomes. For example, in December 2023, the IBD Registry, a UK-based non-profit organization, reported that over 5,300 individuals with inflammatory bowel diseases were registered in 2023, showing an increase of more than 3,000 members compared to 2022. Thus, the growing incidence of inflammatory bowel diseases is boosting the gastrointestinal therapeutics market.

Leading companies in the gastrointestinal therapeutics market are focusing on innovative treatments, such as sustained-release (SR) fixed-dose combination capsules, aimed at enhancing treatment effectiveness and patient adherence. Sustained-release (SR) fixed-dose combination capsules are oral drugs that gradually release multiple active ingredients over time, ensuring stable drug levels and reducing the need for frequent dosing. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical manufacturer, introduced rabeprazole + levosulpiride SR capsules for gastrointestinal disorders in India. This formulation pairs rabeprazole, a proton pump inhibitor that lowers stomach acid, with levosulpiride, a prokinetic that improves gut motility. Together, they provide relief from symptoms like heartburn, acid reflux, bloating, and indigestion, and are commonly prescribed for conditions such as gastroesophageal reflux disease, peptic ulcers, and related gastrointestinal issues.

In April 2023, Merck and Co., Inc., a US pharmaceutical company, acquired Prometheus Biosciences, Inc. for $10.8 billion. This acquisition is intended to strengthen Merck’s immunology pipeline by advancing precision therapies for inflammatory diseases, including ulcerative colitis and Crohn’s disease. Prometheus Biosciences, Inc., based in the US, specializes in precision therapeutics for immune-mediated disorders, particularly those affecting the gastrointestinal system.

Major players in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, Olympus Corporation, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the gastrointestinal therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastrointestinal therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastrointestinal therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastrointestinal therapeutics market consists of sales of acid suppressants, antiemetic agents, antispasmodics, digestive enzymes, and prebiotics and probiotics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The gastrointestinal therapeutics market research report is one of a series of new reports that provides gastrointestinal therapeutics market statistics, including gastrointestinal therapeutics global market size, regional shares, competitors with gastrointestinal therapeutics market share, detailed gastrointestinal therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gastrointestinal therapeutics industry. The gastrointestinal therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastrointestinal therapeutics encompass a variety of drugs, biologics, and treatment options aimed at preventing, managing, or curing disorders of the gastrointestinal system, which includes the esophagus, stomach, intestines, liver, pancreas, and gallbladder. These treatments address conditions like acid reflux, ulcers, irritable bowel syndrome, Crohn’s disease, and gastrointestinal cancers.

The primary categories of gastrointestinal therapeutics include over-the-counter (OTC) and prescription-based products. OTC gastrointestinal therapeutics consist of non-prescription medications designed to alleviate common digestive problems such as heartburn, indigestion, gas, constipation, and diarrhea. These therapies can be administered via different routes, including oral and intravenous methods. They are used to treat various conditions such as inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, and irritable bowel syndrome. Distribution of these products occurs through hospital pharmacies, retail pharmacies, online pharmacies, and more. End users range from hospitals and clinics to ambulatory surgical centers and diagnostic laboratories.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.